Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 1.5% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 481,146 shares of the medical research company’s stock after purchasing an additional 7,177 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.94% of Charles River Laboratories International worth $101,161,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Beverly Hills Private Wealth LLC boosted its position in Charles River Laboratories International by 144.3% in the 2nd quarter. Beverly Hills Private Wealth LLC now owns 4,884 shares of the medical research company’s stock worth $1,010,000 after purchasing an additional 2,885 shares in the last quarter. Cetera Investment Advisers boosted its position in Charles River Laboratories International by 55.2% in the 2nd quarter. Cetera Investment Advisers now owns 2,792 shares of the medical research company’s stock worth $587,000 after purchasing an additional 993 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Charles River Laboratories International by 9.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 385,126 shares of the medical research company’s stock worth $80,973,000 after purchasing an additional 31,705 shares in the last quarter. Banque Cantonale Vaudoise boosted its position in Charles River Laboratories International by 7.4% in the 2nd quarter. Banque Cantonale Vaudoise now owns 2,755 shares of the medical research company’s stock worth $579,000 after purchasing an additional 191 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in Charles River Laboratories International by 3.5% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 8,926 shares of the medical research company’s stock worth $1,877,000 after purchasing an additional 301 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Activity

In related news, Director Richard F. Wallman bought 1,000 shares of the company’s stock in a transaction dated Thursday, August 24th. The shares were acquired at an average price of $198.79 per share, with a total value of $198,790.00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at approximately $198,790. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Charles River Laboratories International news, Director Richard F. Wallman acquired 1,000 shares of the company’s stock in a transaction that occurred on Thursday, August 24th. The shares were purchased at an average price of $198.79 per share, with a total value of $198,790.00. Following the completion of the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $198,790. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO James C. Foster acquired 5,620 shares of the company’s stock in a transaction that occurred on Tuesday, November 14th. The shares were acquired at an average cost of $178.05 per share, for a total transaction of $1,000,641.00. Following the acquisition, the chief executive officer now directly owns 202,643 shares of the company’s stock, valued at $36,080,586.15. The disclosure for this purchase can be found here. Corporate insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on CRL shares. Guggenheim lowered their price objective on Charles River Laboratories International from $255.00 to $225.00 and set a “buy” rating on the stock in a research report on Friday, September 22nd. StockNews.com assumed coverage on Charles River Laboratories International in a research report on Thursday, October 5th. They issued a “hold” rating on the stock. JPMorgan Chase & Co. increased their target price on Charles River Laboratories International from $225.00 to $250.00 and gave the company an “overweight” rating in a research report on Thursday, August 10th. Bank of America decreased their target price on Charles River Laboratories International from $245.00 to $230.00 in a research report on Friday, September 22nd. Finally, Morgan Stanley decreased their target price on Charles River Laboratories International from $220.00 to $205.00 and set an “equal weight” rating on the stock in a research report on Friday, November 10th. Five analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $232.54.

Charles River Laboratories International Trading Up 0.8 %

CRL opened at $190.53 on Tuesday. The firm has a market cap of $9.77 billion, a price-to-earnings ratio of 20.62, a price-to-earnings-growth ratio of 2.00 and a beta of 1.35. Charles River Laboratories International, Inc. has a 52 week low of $161.65 and a 52 week high of $262.00. The business’s 50 day moving average is $188.36 and its two-hundred day moving average is $198.29. The company has a quick ratio of 1.16, a current ratio of 1.45 and a debt-to-equity ratio of 0.76.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, November 8th. The medical research company reported $2.72 EPS for the quarter, topping the consensus estimate of $2.35 by $0.37. The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1 billion. Charles River Laboratories International had a return on equity of 18.15% and a net margin of 11.27%. The firm’s revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.63 earnings per share. On average, research analysts predict that Charles River Laboratories International, Inc. will post 10.58 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).